Infectious Diseases

How Well Does the J&J Vaccine Work Against the Delta Variant?

That’s a question that’s on a lot of people’s minds, because frankly, we have answers that seem to disagree with each other. Let’s have a look: For one, there’s this letter in the NEJM from researchers at Beth Israel Deaconess hospital and from Janssen (J&J’s pharma branch). That’s a look at immunity in 20 patients …

How Well Does the J&J Vaccine Work Against the Delta Variant? Read More »

Why Are Women and Men So Different in Autoimmune Disease?

That last post on vaccine reactions mentioned autotimmune disease several times, and that brings up a question that’s been outstanding for many decades now. If you look at the distribution of most autoimmune syndromes in the population, you find many obvious differences between male and female incidence rates. Guillain-Barré (discussed yesterday) is less common in women …

Why Are Women and Men So Different in Autoimmune Disease? Read More »

Oxford drugs firm gains $1.5m Gates grant for Covid-19 therapy

Exclusive: Exscientia to use AI in proposed fast-track development of ‘low-cost’ pill for Sars viruses Coronavirus – latest updates See all our coronavirus coverage Exscientia, an Oxford-based firm that uses artificial intelligence to develop medicines, has won a $1.5m grant from the Bill & Melinda Gates Foundation to create a Covid-19 treatment that also works …

Oxford drugs firm gains $1.5m Gates grant for Covid-19 therapy Read More »

Million Pfizer jabs face being dumped after Israel-UK swap deal fails

Israel says technical issues have scuppered deal to give UK Covid vaccines expiring on 30 July Coronavirus – latest updates See all our coronavirus coverage More than a million Pfizer/BioNTech vaccine doses held in Israel that are due to expire at the end of July may be thrown away after attempts to broker a swap …

Million Pfizer jabs face being dumped after Israel-UK swap deal fails Read More »

What mRNA is Good For, And What It Maybe Isn’t

The huge success of the mRNA vaccination platform during the pandemic has set a lot of people to thinking about what comes next. Moderna and BioNTech, of course, have been thinking this way for quite some time. But Sanofi now says that they’ll be investing large amounts into the technology, and this previously hadn’t been …

What mRNA is Good For, And What It Maybe Isn’t Read More »

The Oxford vaccine: the trials and tribulations of a world-saving jab

Amid bemusement from scientists at the deluge of often undeserved criticism, the Guardian pieces together the story behind the vaccine’s successes and failures Coronavirus – latest updates See all our coronavirus coverage In January 2020, when most of the world slept soundly in ignorance of the pandemic coming its way, a group of scientists at …

The Oxford vaccine: the trials and tribulations of a world-saving jab Read More »

Moderna, Pfizer or AstraZeneca? The ridiculous, diverting rise of vaccine envy

Casual vaccine chat is today’s only form of small talk, so it’s not surprising it would take a lightheartedly tribal turn. Ultimately, of course, gratitude is at the heart of the conversation Last week, I had cause to go searching for images of men getting vaccinated (it’s not a fetish – it was for work) …

Moderna, Pfizer or AstraZeneca? The ridiculous, diverting rise of vaccine envy Read More »

Western countries must share Covid vaccines – if only for the sake of their GDP

Optimistic forecasts about ‘bouncing back’ will only come true if new variants do not close borders and devastate trade again Coronavirus – latest updates See all our coronavirus coverage The world economy is on course to bounce back from the pandemic with a momentum that will carry through to next year and beyond. This prediction, …

Western countries must share Covid vaccines – if only for the sake of their GDP Read More »

Covid jabs for billions of humans will earn their makers billions of dollars

We look at the drug firms – led by Pfizer and Moderna – that are set to profit most in an unprecedented global vaccination drive Coronavirus – latest updates See all our coronavirus coverage Drugmakers led by US firms Pfizer and Moderna stand to make tens of billions of dollars from their Covid-19 vaccines this …

Covid jabs for billions of humans will earn their makers billions of dollars Read More »

Drop Covid vaccine patent rules to save lives in world’s poorest countries, Britain and Germany told

G7 summit hears move would slash the cost of jabs and accelerate the rollout of programmes across the developing world Britain and Germany were last night under intense pressure to drop their resistance to proposals that would slash the cost of Covid-19 vaccines, following accusations that an agreement at the G7 summit to fund a …

Drop Covid vaccine patent rules to save lives in world’s poorest countries, Britain and Germany told Read More »

More research funding needed to avoid drug-resistant pandemic, warns report

Smaller firms are developing most antibiotics targeting superbugs but often at risk of bankruptcy Small drugmakers and biotech firms that are developing the bulk of new antibiotics need far more financial support, according to a new report, which warned that without these life-saving medicines there could be a pandemic of drug-resistant infections, worse than Covid-19. …

More research funding needed to avoid drug-resistant pandemic, warns report Read More »

Japan approves two more COVID vaccines as fourth infection wave hits

Japan has approved two more coronavirus vaccines, while expanding a state of emergency to cover the southern island of Okinawa. The two newly approved vaccines are from Moderna and AstraZeneca and will be added to a vaccine drive that began in mid-February using the Pfizer/BioNTech shot. However Reuters reported that the AstraZeneca vaccine will not …

Japan approves two more COVID vaccines as fourth infection wave hits Read More »

Sanofi/GSK move latecomer COVID-19 shot into phase 3

Sanofi and GlaxoSmithKline seem to be getting somewhere with their COVID-19 vaccine at last, announcing plans to move to phase 3 following supportive mid-stage trial results. In a statement the companies said that if the late-stage trial and regulatory reviews go well, the vaccine is expected to be approved in the fourth quarter of this …

Sanofi/GSK move latecomer COVID-19 shot into phase 3 Read More »

Delay in giving second jabs of Pfizer vaccine improves immunity

Study finds antibodies against Sars-CoV-2 three-and-a-half times higher in people vaccinated again after 12 weeks rather than three Coronavirus – latest updates See all our coronavirus coverage The UK’s decision to delay second doses of coronavirus vaccines has received fresh support from research on the over-80s which found that giving the Pfizer/BioNTech booster after 12 …

Delay in giving second jabs of Pfizer vaccine improves immunity Read More »

Pfizer warns Australia a Covid vaccine patent waiver could harm supply and safety

The pharmaceutical giant argues waiving intellectual property protections could see scarce inputs snapped up making it harder to produce vaccines Full Story podcast: Is Australia stopping the world’s poorest nations from accessing cheap vaccines? What is patent waiving and will it solve the global shortage? Pfizer has warned Australia against joining a growing push to …

Pfizer warns Australia a Covid vaccine patent waiver could harm supply and safety Read More »

EU wants to mass produce three ‘course-changing’ Covid drugs from October

Health commissioner says plan is to reduce hospitalisation and tackle long-term impact of Covid Coronavirus – latest updates See all our coronavirus coverage Three Covid medicines with the potential to “change the course” of the pandemic will be authorised for mass production and use in the EU by October under a European Commission plan. Stella …

EU wants to mass produce three ‘course-changing’ Covid drugs from October Read More »

India wants access to cheap copies of Covid vaccines. So why is Australia holding out?

More than 100 countries are pushing for a temporary waiver of IP rules to boost vaccine access for developing nations. Why hasn’t it been approved? As India grapples with a devastating Covid wave that has overwhelmed its hospitals, offers of aid, including from Australia, have flooded in from around the world. The help on offer …

India wants access to cheap copies of Covid vaccines. So why is Australia holding out? Read More »

Oxford’s malaria shot set for phase 3 test after ‘unprecedented’ 77% efficacy

Following the success of the coronavirus vaccine developed with AstraZeneca, Oxford University’s Jenner Institute has unveiled trial results showing its experimental malaria shot could be around 77% effective. There is a malaria vaccine on the market – GlaxoSmithKline’s Mosquirix – but this is only around 39% effective in young children and has not been backed …

Oxford’s malaria shot set for phase 3 test after ‘unprecedented’ 77% efficacy Read More »

What Covid vaccines does the UK have and which are in the works?

As Valneva recruits volunteers for final stage trials of its vaccine, here is the current state of play in Britain Coronavirus – latest updates See all our coronavirus coverage Vaccines to protect against the coronavirus were designed, tested and manufactured in record time, and several have been approved for use in the UK vaccination programme, …

What Covid vaccines does the UK have and which are in the works? Read More »

In the fight against Covid, have we been inoculated against compassion? | Letters

Dr Mohga Kamal-Yanni says world leaders must stop putting big pharma’s profits before people’s lives. Sue Hoar wonders why more is not being done to help Covid patients in India The shortfall in Covid vaccine doses going to the Covax vaccine-sharing scheme is deeply worrying, and highlights a massive flaw in the plans to provide …

In the fight against Covid, have we been inoculated against compassion? | Letters Read More »

The world is desperate for more Covid vaccines – patents shouldn’t get in the way | Stephen Buranyi

Pharmaceutical companies insist secrecy is the only way. But what if they were obliged to share recipes and supply chains? Biolyse is a small pharmaceutical manufacturer in Canada with a simple proposition: provide a recipe for a coronavirus vaccine, and it will produce 20m doses for nations in the global south. It has approached AstraZeneca …

The world is desperate for more Covid vaccines – patents shouldn’t get in the way | Stephen Buranyi Read More »

Great Malaria Vaccine News

Excellent news today: we have word of the most effective malaria vaccine yet discovered. A year-long trial in Burkina Faso has shown 77% efficacy, which is by far the record, and which opens the way to potentially relieving a nearly incalculable burden of disease and human suffering. This is a collaboration between the University of …

Great Malaria Vaccine News Read More »

Three Advantages of LTACHs: Research Supports the Important Role LTACHs Play as Post-Acute Partners

<div class="right-align"> <a class="btn btn-blue _gt" data-category="Hospital" data-action="Click-Button" data-label="Blog-Three Advantages of LTACHs" href="https://www.kindredhealthcare.com/docs/default-source/default-document-library/hd-three-advantages-of-ltachs.pdf?sfvrsn=44449eea_2" title="Three Advantages of LTACHs: Research Strongly Suggests That LTACHs Play an Important Role as Post-Acute Partners" target="_blank">Download this article as a PDF</a></div> <br /> <p>In today&rsquo;s intense healthcare environment, partnerships between acute and post-acute providers have been particularly essential. Though all post-acute …

Three Advantages of LTACHs: Research Supports the Important Role LTACHs Play as Post-Acute Partners Read More »

Three Advantages of LTACHs: Research Strongly Suggests That LTACHs Play an Important Role as Post-Acute Partners

<div class="right-align"> <a class="btn btn-blue _gt" data-category="Hospital" data-action="Click-Button" data-label="Blog-Three Advantages of LTACHs" href="https://www.kindredhealthcare.com/docs/default-source/default-document-library/hd-three-advantages-of-ltachs.pdf?sfvrsn=44449eea_2" title="Three Advantages of LTACHs: Research Strongly Suggests That LTACHs Play an Important Role as Post-Acute Partners" target="_blank">Download this article as a PDF</a></div> <br /> <p>In today&rsquo;s intense healthcare environment, partnerships between acute and post-acute providers have been particularly essential. Though all post-acute …

Three Advantages of LTACHs: Research Strongly Suggests That LTACHs Play an Important Role as Post-Acute Partners Read More »

Oxford/AstraZeneca Covid vaccine research ‘was 97% publicly funded’

Analysis rebuts claim by Boris Johnson that jab was developed ‘because of greed’ Coronavirus – latest updates See all our coronavirus coverage At least 97% of the funding for the development of the Oxford/AstraZeneca Covid-19 vaccine has been identified as coming from taxpayers or charitable trusts, according to the first attempt to reconstruct who paid …

Oxford/AstraZeneca Covid vaccine research ‘was 97% publicly funded’ Read More »

Will Covid vaccines protect us against new variants? | Julian Tang

New strains such as the South African variant that’s emerged in south London will require constant vigilance as lockdown eases All viruses mutate. They do this to adapt and survive better in their specific host. The virus that causes Covid-19 is no different: it has moved from the animal realm, where it most likely originated …

Will Covid vaccines protect us against new variants? | Julian Tang Read More »

UK strategy of backing several Covid vaccines seems to be paying off

Analysis: buying new and existing technologies ensured alternatives if a vaccine failed or had supply issues Coronavirus – latest updates See all our coronavirus coverage The government has said the decision by Johnson & Johnson to delay the supply of its Covid vaccine to Europe, while the US investigates reports of six cases of unusual …

UK strategy of backing several Covid vaccines seems to be paying off Read More »

EU seeking ‘urgent clarification’ on Johnson & Johnson Covid vaccine delay

Company has said it is postponing deployment in Europe following concerns about blood clots in US Coronavirus – latest updates See all our coronavirus coverage The European commission is seeking “urgent clarification” from Johnson & Johnson after the company’s “completely unexpected” announcement that it has decided to delay the deployment of its coronavirus vaccine across …

EU seeking ‘urgent clarification’ on Johnson & Johnson Covid vaccine delay Read More »

England begins Moderna vaccine rollout as lockdown eases

England is beginning its rollout of the Moderna COVID-19 vaccine, offering an alternative to the AstraZeneca/Oxford University jab following a potential link to a very rare kind of blood clot. The Moderna shot is the third vaccine to become available in the country, which has made considerable progress with its inoculation campaign. Its arrival is …

England begins Moderna vaccine rollout as lockdown eases Read More »

Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trial

Antios has raised $96 million in Series B financing to support the ongoing phase 2 development of its hepatitis B drug candidate, ATI-2173. There are several competitors developing treatments for hepatitis B in what could turn out to be a competitive market. Most people infected with the disease, which can be spread sexually or by …

Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trial Read More »

African health workers left without Covid jabs as paltry supplies dwindle

Fear of third wave and new variants as sub-Saharan vaccine distribution is dogged by supply disruption Coronavirus – latest updates See all our coronavirus coverage Millions of healthcare workers in sub-Saharan Africa continue to risk their lives to fight Covid-19 as authorities across the continent struggle to obtain and distribute vaccines to frontline medical staff. …

African health workers left without Covid jabs as paltry supplies dwindle Read More »

South African variant may evade Pfizer/BioNTech vaccine, study finds

The coronavirus variant discovered in South Africa may evade Pfizer/BioNTech’s vaccine, according to a real-world data study conducted in Israel. Known as variant B.1.351, the variant was found to make up around 1% of all COVID-19 cases across the people studied according to results which have yet to be peer-reviewed. But among patients who had …

South African variant may evade Pfizer/BioNTech vaccine, study finds Read More »

Regeneron to ask FDA to use antibody to prevent COVID-19

Regeneron is to ask the FDA for clearance to use its antibody cocktail as a preventive treatment for COVID-19. The therapy is already authorised by the FDA for adults with mild-to-moderate disease and paediatric patients at least 12 years of age who have tested positive for the virus and are at high risk of serious …

Regeneron to ask FDA to use antibody to prevent COVID-19 Read More »

Global Covid vaccine rollout threatened by shortage of vital components

Pharmaceutical firms warn of delays to items such as the large bags in which vaccine cells are grown Coronavirus – latest updates See all our coronavirus coverage Vaccine-makers around the world face shortages of vital components including large plastic growbags, according to the head of the firm that is manufacturing a quarter of the UK’s …

Global Covid vaccine rollout threatened by shortage of vital components Read More »

AstraZeneca jab worry may play into hands of anti-vaxxers, say Tories

Iain Duncan Smith, former leader, and another MP, warn of eroded confidence in vaccine plan after ‘messy’ MHRA advice Coronavirus – latest updates See all our coronavirus coverage A decision to offer people under 30 an alternative vaccine to the AstraZeneca jab has prompted concern that some could shun the injection over fears about its …

AstraZeneca jab worry may play into hands of anti-vaxxers, say Tories Read More »

Medicines watchdog says no decision made AstraZeneca jab for under-30s

Medicines Healthcare products Regulatory Authority was considering restricting vaccine amid concerns over rare blood clots Coronavirus – latest updates See all our coronavirus coverage The UK’s medicines regulatory body has said that no decision has been made on any regulatory action relating to the Oxford/AstraZeneca vaccine following reports it is considering restricting use of the …

Medicines watchdog says no decision made AstraZeneca jab for under-30s Read More »

Blood clot cases ‘could dent faith of young women in AstraZeneca’

Experts urge public to go for inoculations as benefits far outweigh potential complications Coronavirus – latest updates See all our coronavirus coverage Health officials are becoming increasingly worried that younger people will reject Covid jabs as concerns about the AstraZeneca vaccine continue to grow. A total of 30 cases of rare blood clots have been …

Blood clot cases ‘could dent faith of young women in AstraZeneca’ Read More »

Two new vaccines on the way – with more to follow this year

Half of UK adults have had a first jab, and future supplies of millions of doses look assured Coronavirus – latest updates See all our coronavirus coverage Two very different jabs have been responsible for inoculating Britain’s strikingly high number of vaccine recipients – with more than half of the country’s adult population having now …

Two new vaccines on the way – with more to follow this year Read More »

Canada suspends use of AstraZeneca Covid vaccine for those under 55

Immunisation panel says there is ‘substantial uncertainty about the benefit’ of the vaccine given risk of rare type of blood clot See all our coronavirus coverage Canada on Monday suspended the use of the Oxford/AstraZeneca coronavirus vaccine for people under 55 following concerns it might be linked to rare blood clots. The pause was recommended …

Canada suspends use of AstraZeneca Covid vaccine for those under 55 Read More »

Safe, stable, sold at cost: AstraZeneca’s vaccine deserves celebration, not scorn

The company has struggled, like its rivals, to keep up with demand. But it has achieved great things at low prices AstraZeneca is one of the shining stars of the pandemic. Not only did it produce a vaccine where other big players failed, the UK-Swedish company has pledged to sell it at cost until it …

Safe, stable, sold at cost: AstraZeneca’s vaccine deserves celebration, not scorn Read More »

How the AstraZeneca vaccine became a political football – and a PR disaster

Newly accused of data manipulation by the US, AstraZeneca has faced unprecedented scrutiny over the past six months Coronavirus – latest updates See all our coronavirus coverage It was billed as the vaccine to deliver the world from Covid. But over the last six months, AstraZeneca – whose jab was designed to save thousands of …

How the AstraZeneca vaccine became a political football – and a PR disaster Read More »

Regeneron’s antibody cocktail cuts COVID hospitalisation in large trial

Regeneron has posted findings from a large trial its COVID-19 antibody cocktail showing it reduced risk of hospitalisation or death by 70%. The US pharma said that the results were a landmark as they “conclusively” demonstrated that REGEN-COV (casirivimab+imdevimab) can significantly reduce death in an outpatient setting. Data from the phase 3 trial will also …

Regeneron’s antibody cocktail cuts COVID hospitalisation in large trial Read More »

Pfizer begins clinical trials of COVID-19 antiviral pill

Pfizer has begun clinical development of an antiviral pill against COVID-19, which could be prescribed to patients at the first sign of infection. The company was the first to get a vaccine approved against the disease with BioNTech and is now aiming to make a pill that could prevent it escalating once patients are infected. …

Pfizer begins clinical trials of COVID-19 antiviral pill Read More »

The Guardian view on pandemic politics: we need cooperation, not confrontation | Editorial

Vaccinating the world is the only way out of Covid, but a mixture of nationalism and protectionism is blocking the exit Covid-19 has proved to be the greatest humanitarian and economic disaster of the century. A reported 2.7 million people have already died from the pathogen. Its recession is estimated to be twice as deep …

The Guardian view on pandemic politics: we need cooperation, not confrontation | Editorial Read More »

Vaccine wars: the week that rocked the UK’s Covid jab rollout

After a week of bans, U-turns and warnings of supply shortfalls, public confidence in vaccination has been dented. Can Britain get back on the fast track out of lockdown? Coronavirus – latest updates See all our coronavirus coverage For Stacey Harris, the hardest part of organising vaccinations over the last couple of months has been …

Vaccine wars: the week that rocked the UK’s Covid jab rollout Read More »

France limits AstraZeneca Covid jab to over-55s as Europe treads cautiously

Three Scandinavian countries reserve judgment one day after EMA says shot is safe and effective Coronavirus – latest updates See all our coronavirus coverage France has said only people aged 55 and over should receive the AstraZeneca Covid-19 vaccine, and three Scandinavian countries have reserved judgment until next week, a day after Europe’s health regulator …

France limits AstraZeneca Covid jab to over-55s as Europe treads cautiously Read More »

France limits AstraZeneca Covid jab to over-55s as Europe treads cautiously

Three Scandinavian countries reserve judgment one day after EMA says shot is safe and effective Coronavirus – latest updates See all our coronavirus coverage France has said only people aged 55 and over should receive the AstraZeneca Covid-19 vaccine, and three Scandinavian countries have reserved judgment until next week, a day after Europe’s health regulator …

France limits AstraZeneca Covid jab to over-55s as Europe treads cautiously Read More »

Patrick Vallance: the adviser who spoke scientific truth to power

The UK’s chief scientific adviser loves good food, enjoys a Scandi drama – and has been called ‘the richest civil servant in history’ Sir Patrick Vallance spent his 60th birthday at a podium in Downing Street, flanking Boris Johnson. Whatever plans he had were scrapped. Continue reading…

Patrick Vallance: the adviser who spoke scientific truth to power

The UK’s chief scientific adviser loves good food, enjoys a Scandi drama – and has been called ‘the richest civil servant in history’ Sir Patrick Vallance spent his 60th birthday at a podium in Downing Street, flanking Boris Johnson. Whatever plans he had were scrapped. Continue reading…

Could a smartphone cough app stop future pandemics?

A host of companies are looking at cough apps to detect the presence of COVID-19. But one company called Hyfe wants to take the idea a step further and use them to detect future pandemics, reports Richard Staines.  The pandemic has seen a plethora of digital tools emerge to help manage patients remotely, with the …

Could a smartphone cough app stop future pandemics? Read More »

Could a smartphone cough app stop future pandemics?

A host of companies are looking at cough apps to detect the presence of COVID-19. But one company called Hyfe wants to take the idea a step further and use them to detect future pandemics, reports Richard Staines.  The pandemic has seen a plethora of digital tools emerge to help manage patients remotely, with the …

Could a smartphone cough app stop future pandemics? Read More »

Regulators questioned integrity of Pfizer/BioNTech vaccine, leaked files show

European regulators questioned the integrity of early batches of Pfizer/BioNTech’s mRNA vaccine, although the matter was resolved before approval, according to information leaked online following a cyberattack. As it conducted its analysis of the vaccine in December, the European Medicines Agency’s systems were targeted by unknown hackers. Following this, more than 40 megabytes of classified …

Regulators questioned integrity of Pfizer/BioNTech vaccine, leaked files show Read More »

Benefits of Oxford/AstraZeneca vaccine outweigh any risk, says EMA

European agency seeks to allay blood clot fears as Germany, France and Italy temporarily suspend use Coronavirus – latest updates See all our coronavirus coverage Europe’s medicines regulator has moved to stifle spiralling concern about the Oxford/AstraZeneca vaccine, saying the shot’s benefits outweigh the risks after four major EU countries announced they were suspending its …

Benefits of Oxford/AstraZeneca vaccine outweigh any risk, says EMA Read More »

Ireland suspends AstraZeneca Covid vaccine over blood clot concerns

Deployment of Oxford vaccine temporarily deferred after latest reports from Norway Coronavirus – latest updates See all our coronavirus coverage Ireland is suspending use of the Oxford/AstraZeneca vaccine against Covid as a precautionary measure following further reports of blood clots in people who have received it, this time from Norway. The deputy chief medical officer, …

Ireland suspends AstraZeneca Covid vaccine over blood clot concerns Read More »

Pharma poised to cash in on ‘long COVID’ symptoms

While there’s hope that vaccination campaigns may bring the pandemic under control, “long COVID” side effects may continue to affect patients for some time. According to analysts from Jefferies, several pharma companies could stand to benefit with products that could help with issues such as mental health, lung scarring, kidney disease and heart failure. Although …

Pharma poised to cash in on ‘long COVID’ symptoms Read More »

At AstraZeneca, we know that until everyone is safe from Covid, no one is safe | Pascal Soriot

The scientific community are rising to the challenge, undertaking an unprecedented global health programme Pascal Soriot is the chief executive officer of AstraZeneca Coronavirus – latest updates See all our coronavirus coverage Covid-19 is a virus that knows no boundaries and has inflicted terrible suffering across the world. Now more than ever, we must remember …

At AstraZeneca, we know that until everyone is safe from Covid, no one is safe | Pascal Soriot Read More »

From Pfizer to Moderna: who’s making billions from Covid vaccines?

The companies in line for the biggest gains – and the shareholders who have already made fortunes Coronavirus – latest updates See all our coronavirus coverage The arrival of Covid-19 vaccines promises a return to more normal life – and has created a global market worth tens of billions of dollars in annual sales for …

From Pfizer to Moderna: who’s making billions from Covid vaccines? Read More »

‘Vaccine, vaccine’: Dolly Parton urges Americans to get COVID-19 shots

Efforts to encourage US citizens to take their COVID-19 vaccines received a boost from country music legend Dolly Parton, who updated her hit song “Jolene” to pledge her support in a social media video showing her getting inoculated. Parton burst into a version of her hit, which she wrote and recorded in 1973, before receiving …

‘Vaccine, vaccine’: Dolly Parton urges Americans to get COVID-19 shots Read More »

Genetic Vaccine Development for Infectious Diseases Summit

The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. A combination of urgent need, unprecedented investments, and advances in genetic engineering has allowed what was once mere speculation to become not only our reality, but our future. With pandemic vaccines now launching …

Genetic Vaccine Development for Infectious Diseases Summit Read More »

Covid: Germany and France under pressure to shift Oxford vaccine

Both countries urged to take action to avoid pile-up of unused AstraZeneca vaccine doses Coronavirus – latest updates See all our coronavirus coverage Authorities in Germany and France are under pressure to come up with creative solutions to shift the AstraZeneca vaccine at higher speed in order to avoid a pile-up of unused doses over …

Covid: Germany and France under pressure to shift Oxford vaccine Read More »

Germany signals AstraZeneca vaccine may be approved for over-65s

Healthcare regulator says it will update recommendations ‘very soon’ in wake of row over jab’s effectiveness in older candidates Coronavirus – latest updates See all our coronavirus coverage Germany could soon authorise the use of the AstraZeneca vaccine for seniors after the head of the country’s vaccination committee said his body’s advice to give the …

Germany signals AstraZeneca vaccine may be approved for over-65s Read More »

Altimmune begins trial of nasal vaccine for COVID-19

Pfizer/BioNTech’s mRNA vaccine against COVID is a technical marvel – but the ultra-cool temperatures required for storage and stability has been tricky to handle. Maryland, US-based company Altimmune is among the biotechs and research labs trying to find more convenient alternatives and believes a nasal vaccine spray that is stable at room temperature could be …

Altimmune begins trial of nasal vaccine for COVID-19 Read More »

Pfizer files tick-borne encephalitis shot with FDA

Pfizer may have been making headlines with the COVID vaccine it developed with BioNTech, but it’s not the only infectious disease the big pharma is targeting. In a statement, Pfizer said the FDA has granted a fast review for TicoVac tick-borne encephalitis (TBE) vaccine, to prevent the disease in individuals one year of age or …

Pfizer files tick-borne encephalitis shot with FDA Read More »

German politicians counter AstraZeneca vaccine scepticism with show of support

Oxford Covid vaccine described in German media as ‘shelf warmer’ with only 17% of doses administered so far Coronavirus – latest updates See all our coronavirus coverage Politicians in Germany are stepping out in support of the AstraZeneca vaccine as public scepticism around the Oxford-developed product is threatening to hamper Europe’s Covid-19 immunisation programme. The …

German politicians counter AstraZeneca vaccine scepticism with show of support Read More »

Novavax provides 1.1 billion COVID shots to global vaccine drive

Novavax has signed a deal to provide 1.1 billion doses of its COVID-19 vaccine to the COVAX global initiative led by Gavi, the vaccine alliance, which aims to ensure fair access across the globe. There are growing concerns about the lack of COVID vaccines available to poorer countries. This week UK prime minister Boris Johnson …

Novavax provides 1.1 billion COVID shots to global vaccine drive Read More »

Could CRISPR cure HIV? US biotech Excision raises $60m to find out

US biotech Excision BioTherapeutics has raised $60 million to test a potential HIV cure in the clinic, which would use CRISPR technology to snip out the viral code from human cells and tissues. Once someone is infected with HIV it stays with them for life thanks to the retrovirus’s ability to inject its DNA code …

Could CRISPR cure HIV? US biotech Excision raises $60m to find out Read More »

South Africa leads backlash against big pharma over access to Covid vaccines

Pressure mounts for patent waivers to allow poorer countries to develop their own manufacturing capacity to boost availability The domination of global medicine by major pharmaceutical companies needs to be confronted to provide fairer access to vaccines, a leading South African official has said. The scramble over Covid vaccines should alert rich countries to the …

South Africa leads backlash against big pharma over access to Covid vaccines Read More »

GSK expands coronavirus antibody tie-up to include potential flu therapies

GlaxoSmithKline is expanding a coronavirus antibody collaboration with US biotech Vir, to include potential therapies for flu and other respiratory viruses. The big UK pharma is already working with Vir on antibody therapies for coronaviruses, and already have the antibody VIR-7831 in clinical trials including the US National Institutes of Health-backed ACTIV-3 study. Several firms …

GSK expands coronavirus antibody tie-up to include potential flu therapies Read More »

Guinea declares Ebola epidemic following first deaths since 2016

Guinea has officially declared it is dealing with an Ebola epidemic, after at least three people died from the virus. The BBC reported that these first deaths from Ebola since 2016 were linked to the burial of a nurse, where four others fell ill with diarrhoea, vomiting and bleeding. Newly developed vaccines will be supplied …

Guinea declares Ebola epidemic following first deaths since 2016 Read More »

UK government mulls lockdown review as it hits 15m COVID vaccine target

More than 15 million people in the UK have had their first coronavirus vaccine, described as a ‘significant milestone’ by prime minister Boris Johnson. While the UK was slow to react to the first wave of the pandemic a year ago, it has mounted one of the fastest vaccination programmes in the world. The first …

UK government mulls lockdown review as it hits 15m COVID vaccine target Read More »

Life savers: the amazing story of the Oxford/AstraZeneca Covid vaccine

A year ago, two scientists began work on the response to a new virus. Now, as their vaccine is being given to millions, they tell of their incredible 12 months Exactly a year ago, Oxford University scientists launched a joint enterprise that is set to have a profound impact on the health of our planet. …

Life savers: the amazing story of the Oxford/AstraZeneca Covid vaccine Read More »

‘It shows what we’re capable of’: the NHS’s vaccine triumph

A huge effort has helped the UK provide 14m first doses of Covid vaccines in about two months Coronavirus – latest updates See all our coronavirus coverage In St Albans, GPs took over a former nightclub to provide Covid vaccinations every 20 seconds; in Carnforth, Lancashire, delivering jabs was helped by volunteers from the local …

‘It shows what we’re capable of’: the NHS’s vaccine triumph Read More »

AZ’s next-generation COVID-19 vaccine could be ready in autumn

AstraZeneca is aiming to get a next-generation vaccine targeting emerging variants approved and into the arms of patients by the autumn, company representatives said in a press conference. Mene Pangalos, executive vice president of BioPharmaceuticals R&D, said work has already begun to tweak the shot developed with Oxford University to combat the new variants, which …

AZ’s next-generation COVID-19 vaccine could be ready in autumn Read More »

FDA grants emergency licence for Lilly’s COVID-19 antibody combo

The FDA has granted an emergency licence for Eli Lilly’s COVID-19 antibody combination therapy, to reduce chances of high-risk patients progressing from mild to moderate disease to more severe symptoms that may need hospital treatment. The FDA granted an Emergency Use Authorization (EUA) covering patients aged 12 years and over for investigational bamlanivimab (LY-CoV555) 700 …

FDA grants emergency licence for Lilly’s COVID-19 antibody combo Read More »

EU finalises order for 300 million more Pfizer/BioNTech COVID-19 shots

The European Union has rubber-stamped its order for a further 300 million doses of Pfizer/BioNTech’s COVID-19 vaccine, according to press reports. Citing a European Commission spokesperson, Reuters reported the EU had finalised a preliminary contract for 300 million doses that was first announced a month ago. This is on top of the 300 million doses …

EU finalises order for 300 million more Pfizer/BioNTech COVID-19 shots Read More »

A series of knocks: Oxford/AstraZeneca’s bumpy road to Covid vaccine confidence

From doubts about safety in older people to questions about variants, scientists have faced a battle to convince the public and regulators Coronavirus – latest updates See all our coronavirus coverage The Oxford University/AstraZeneca vaccine against Covid has barely been out of the news from the moment the race to protect the world’s population from …

A series of knocks: Oxford/AstraZeneca’s bumpy road to Covid vaccine confidence Read More »

US experts trial AZ’s long-acting COVID-19 antibody combination

An international trial led by US experts is to begin testing AstraZeneca’s long-acting antibody combination therapy to treat COVID-19. The combination known as AZD7442 is to be added to the phase 3 adaptive trial called ACTIV-3, where investigators add new sub-studies of investigational new agents. It is sponsored by the US-government funded by the National …

US experts trial AZ’s long-acting COVID-19 antibody combination Read More »

China approves Sinovac’s coronavirus vaccine

China’s national regulator has approved Sinovac Biotech’s COVID-19 vaccine for use by the general public. This is the second vaccine approved by China’s National Medical Products Administration (NMPA). Both of the vaccines, along with another experimental vaccine from Sinopharm, have been used in China’s vaccination programme. More than 31 million doses have been administered, mainly …

China approves Sinovac’s coronavirus vaccine Read More »

Oxford Covid vaccine 10% effective against South African variant, study suggests

Small-scale trial of vaccine’s efficacy shows it offers very little protection against mild to moderate infection Coronavirus – latest updates See all our coronavirus coverage The Oxford/AstraZeneca vaccine offers as little as 10% protection against the Covid variant first seen in South Africa, researchers have suggested. Scientists who conducted a small-scale trial of the vaccine’s …

Oxford Covid vaccine 10% effective against South African variant, study suggests Read More »

Oxford Covid vaccine just as effective against Kent variant, trials suggest

Scientists behind AstraZeneca vaccine say it has similar efficacy against variant as against original Covid Coronavirus – latest updates See all our coronavirus coverage The Oxford/AstraZeneca coronavirus vaccine is just as effective at fighting the UK variant as it is the original virus, new research suggests. Oxford University researchers who developed the vaccine say it …

Oxford Covid vaccine just as effective against Kent variant, trials suggest Read More »

Veklury rescues Gilead from COVID doldrums in Q4

Gilead’s COVID-19 drug Veklury (remdesivir) is helping the company through disruption caused by the pandemic and patent expiry on two HIV drugs, according to its Q4 results announcement. In the final quarter alone, Veklury generated sales of just over $1.9 billion, offsetting a downturn in sales elsewhere in the business amid the disruption to healthcare …

Veklury rescues Gilead from COVID doldrums in Q4 Read More »

J&J asks FDA for emergence clearance for single-shot COVID-19 vaccine

Johnson & Johnson’s Janssen unit has filed its single dose COVID-19 vaccine candidate with the FDA, asking for an Emergency Use Authorization (EUA). The EUA will be based on the data from the phase 3 ENSEMBLE trial that Janssen announced last week. The European Medicines Agency (EMA) has already begun a rolling review of the …

J&J asks FDA for emergence clearance for single-shot COVID-19 vaccine Read More »

UK reaches 10 million landmark with COVID-19 vaccination programme

The UK has reached a major landmark with its COVID-19 vaccination programme, with more than 10 million people receiving their first shot. After almost a year of restrictions to prevent the virus spreading, there is now hope that normal life may begin to return as data collected separately in Israel showed that vaccination also helps …

UK reaches 10 million landmark with COVID-19 vaccination programme Read More »

One Pfizer/BioNTech jab gives ‘90% immunity’ from Covid after 21 days

New analysis runs counter to earlier study which suggested one dose may not give adequate protection Coronavirus – latest updates See all our coronavirus coverage One dose of the Pfizer/BioNTech vaccine gives people about 90% protection from Covid by 21 days, according to an analysis of Israel’s mass vaccination programme. The data analysis, carried out …

One Pfizer/BioNTech jab gives ‘90% immunity’ from Covid after 21 days Read More »

GSK and CureVac sign £132m deal to develop multi-variant Covid vaccine

Companies hope to have next generation of vaccines against emerging variants by next year GlaxoSmithKline and Germany’s CureVac have reached a €150m (£132m) agreement to develop a next generation of Covid-19 vaccines targeting new emerging variants in the pandemic. The two companies said they they plan to work jointly to develop a vaccine that can …

GSK and CureVac sign £132m deal to develop multi-variant Covid vaccine Read More »

Even with vaccines, we still need treatments for Covid. So what works?

Analysis: death rates in intensive care are falling as doctors identify more ways to help those with the disease Coronavirus – latest updates See all our coronavirus coverage Vaccines may have been described as the great escape route from the Covid pandemic – but treatments, which are bringing down death rates, will be needed as …

Even with vaccines, we still need treatments for Covid. So what works? Read More »

UK vaccine strategy ‘paying off’ as latest trials boost stockpiles

Pre-ordering of Janssen and Novavax means Britain has procured 247m successfully trialled jabs Coronavirus – latest updates See all our coronavirus coverage Britain has cemented its status as one of the world’s leading buyers of effective Covid vaccines after two more pharmaceutical companies reported positive trial results – potentially growing the UK stockpile by 90m …

UK vaccine strategy ‘paying off’ as latest trials boost stockpiles Read More »

Novavax’s COVID-19 shot effective against UK strain

Novavax’s COVID-19 vaccine could be added to the UK’s growing arsenal of shots against the disease after it showed 89.3% efficacy in a late-stage trial. The shot is the first to show efficacy against the new variant found in the UK which accounted for around half of cases in the phase 3 study. Efficacy against …

Novavax’s COVID-19 shot effective against UK strain Read More »

How effective is the Novavax Covid vaccine and will it work against variants?

Everything you need to know about the trial results for a new coronavirus vaccine Coronavirus – latest updates See all our coronavirus coverage In an interim analysis of a phase 3 clinical trial conducted in the UK, the vaccine has been shown to be nearly 89% effective, with 27% of participants in the trial – …

How effective is the Novavax Covid vaccine and will it work against variants? Read More »

How effective is the Novavax Covid vaccine and will it work against variants?

Everything you need to know about the trial results for a new coronavirus vaccine Coronavirus – latest updates See all our coronavirus coverage In an interim analysis of a phase 3 clinical trial conducted in the UK, the vaccine has been shown to be nearly 89% effective, with 27% of participants in the trial – …

How effective is the Novavax Covid vaccine and will it work against variants? Read More »

Novavax Covid vaccine shown to be nearly 90% effective in UK trial

UK vaccines taskforce has bought 60m doses after study found ‘spectacular results’ Coronavirus – latest updates See all our coronavirus coverage Another vaccine against Covid, trialled in the UK and bought by the government, has been shown to be nearly 90% effective and work against the UK and South African variants of the virus. The …

Novavax Covid vaccine shown to be nearly 90% effective in UK trial Read More »

AstraZeneca denies pulling out of talks as EU Covid vaccine row deepens

Latest round of crunch talks to discuss breakdown in supplies still happening, says spokesman Coronavirus – latest updates See all our coronavirus coverage A row over coronavirus vaccine shortages in the EU has descended into farce as AstraZeneca denied claims by the European commission that it had pulled out of a crunch meeting over a …

AstraZeneca denies pulling out of talks as EU Covid vaccine row deepens Read More »

Regeneron and Lilly post new data backing COVID antibody cocktails

Regeneron is considering an emergency filing for its antibody cocktail REGEN-COV to protect people against COVID-19 after early trial results showed it conferred 100% protection against symptomatic infection. The announcement came after Eli Lilly posted results from its rival antibody cocktail, showing hospitalisations were reduced by 70% in high-risk patients. Regeneron’s results are based on …

Regeneron and Lilly post new data backing COVID antibody cocktails Read More »

Head of AstraZeneca rejects calls for UK vaccine to be diverted to EU

Chief executive of pharmaceutical giant says the firm will honour UK’s earlier contract despite EU anger over shortfall Coronavirus – latest updates See all our coronavirus coverage AstraZeneca’s chief executive has insisted the UK will come first for vaccines as he rejected calls to divert doses to the European Union following a breakdown in supply. …

Head of AstraZeneca rejects calls for UK vaccine to be diverted to EU Read More »

EU means business over Covid vaccine exports, says Von der Leyen

Commission president says firms must deliver on orders after AstraZeneca warns of shortfall Coronavirus – latest updates See all our coronavirus coverage The EU “means business”, Ursula von der Leyen has said, as the bloc doubled down on plans for tighter monitoring of vaccine exports to countries outside of the union, such as the UK. …

EU means business over Covid vaccine exports, says Von der Leyen Read More »

Pharmaceutical giants not ready for next pandemic, report warns

Ten of the world’s most infectious diseases identified by the WHO not being catered for by drug firms The world’s biggest pharmaceutical firms are little prepared for the next pandemic despite a mounting response to the Covid-19 outbreak, an independent report has warned. Jayasree K Iyer, executive director of the Netherlands-based Access to Medicine Foundation, …

Pharmaceutical giants not ready for next pandemic, report warns Read More »

German government challenges AstraZeneca Covid vaccine efficacy reports

Newspaper had reported that government was expecting European regulator’s assessment to show that vaccine was only 8% effective among over-65 The German government has challenged reports of a lower-than-expected efficacy rate of the AstraZeneca vaccine for older people, while reiterating concerns about the British-Swedish pharmaceutical giant’s data reporting. An article in German business daily Handelsblatt …

German government challenges AstraZeneca Covid vaccine efficacy reports Read More »

Germany to administer Covid drugs used to treat Donald Trump

Country will be first in EU to use antibody cocktails after government buys 200,000 doses Specialist clinics in Germany will this week become the first hospitals in the EU to treat Covid-19 patients with expensive and experimental antibody cocktails used to treat the former US president Donald Trump after he caught the virus last October. …

Germany to administer Covid drugs used to treat Donald Trump Read More »

Vaccine experts call for clarity on UK’s 12-week Covid jab interval

British Society for Immunology calls for a robust programme monitoring the body’s immune response Experts have called for greater clarity on the monitoring in place to assess the 12-week dosing interval for Covid-19 vaccines, as the row over delayed second doses continues. The UK’s coronavirus vaccination programme was shifted late last year to prioritise administering …

Vaccine experts call for clarity on UK’s 12-week Covid jab interval Read More »

Vaccine experts call for clarity on UK’s 12-week Covid jab interval

British Society for Immunology calls for a robust programme monitoring the body’s immune response Experts have called for greater clarity on the monitoring in place to assess the 12-week dosing interval for Covid-19 vaccines, as the row over delayed second doses continues. The UK’s coronavirus vaccination programme was shifted late last year to prioritise administering …

Vaccine experts call for clarity on UK’s 12-week Covid jab interval Read More »

I’ve had my first vaccine jab. It gives me hope of liberation… but not yet

Exactly a year after his first story about coronavirus, our science editor received the Pfizer injection last week. Here he reflects on a remarkable scientific achievement Coronavirus – latest updates See all our coronavirus coverage I marked a grim anniversary in an unexpected manner last week. On 18 January last year, I wrote my first …

I’ve had my first vaccine jab. It gives me hope of liberation… but not yet Read More »

Vaccine experts defend UK decision to delay second Pfizer Covid jab

Medics told they risk undermining public confidence by querying policy of three-month gap between doses Coronavirus – latest updates See all our coronavirus coverage Leading vaccine experts have backed the government’s decision to delay the second dose for up to three months, after doctors warned that the strategy was proving “ever-more difficult to justify”. The …

Vaccine experts defend UK decision to delay second Pfizer Covid jab Read More »

World’s poor need action, not Covid ‘vaccine nationalism’, say experts

Nations outbidding each other creates an ‘immoral race towards the abyss’ Coronavirus – latest updates See all our coronavirus coverage Pharmaceutical companies should do more to transfer vaccine technology to prevent the poorest countries falling behind in the distribution of Covid-19 vaccines, according to an expert. The warning came from Dag-Inge Ulstein, the co-chair of …

World’s poor need action, not Covid ‘vaccine nationalism’, say experts Read More »

ViiV/J&J’s long-acting HIV regimen finally approved in US

The FDA has approved Cabenuva, a long-acting HIV treatment from ViiV and Johnson & Johnson that keeps the virus at bay with a monthly injection instead of daily pill regimen. It follows a surprise rejection at the end of 2019, due to the information in the dossier related to chemistry, manufacturing and controls (CMC). The …

ViiV/J&J’s long-acting HIV regimen finally approved in US Read More »

ConserV Bioscience works on mutation-proof coronavirus shots with US lab

UK biotech ConserV Bioscience has joined with California’s Lawrence Livermore National Laboratory to develop broad-spectrum coronavirus vaccines as concerns mount over potentially more infectious strains emerging in the UK, South Africa and Brazil. This collaboration brings together ConserV’s expertise in identifying antigens and Lawrence Livermore National Laboratory’s (LLNL) nanolipoprotein particle technology (“NLP”) delivery system. The …

ConserV Bioscience works on mutation-proof coronavirus shots with US lab Read More »

Single Covid vaccine dose in Israel ‘less effective than we hoped’

Surge in infections dampens optimism over country’s advanced immunisation programme Coronavirus – latest updates See all our coronavirus coverage Israel’s coronavirus tsar has warned that a single dose of the Pfizer/BioNtech vaccine may be providing less protection than originally hoped, as the country reported a record 10,000 new Covid infections on Monday. In remarks reported …

Single Covid vaccine dose in Israel ‘less effective than we hoped’ Read More »

ViiV launches digital triage service for HIV patients with London hospital

ViiV Healthcare and London’s Westminster Hospital NHS Foundation Trust have launched a digital triage service for HIV patients supported by a mobile app. ViiV, a joint venture majority owned by GlaxoSmithKline, with Pfizer and Shionogi as minority shareholders, has been working with Chelsea and Westminster Hospital NHS Foundation Trust on the service. The new service …

ViiV launches digital triage service for HIV patients with London hospital Read More »

Fauci backs Biden’s plan for 100 million COVID-19 shots

A promise by president-elect Joe Biden to carry out 100 million coronavirus vaccinations in his first 100 days in power is “absolutely doable”, according to the US leading infectious diseases expert Dr Anthony Fauci. Biden has announced ambitious initiatives to fight COVID-19 ahead of his inauguration, which is due to take place on Wednesday. While …

Fauci backs Biden’s plan for 100 million COVID-19 shots Read More »

UK to face short term delay in delivery of Pfizer vaccine

Overall number of doses delivered between January and March will remain the same, the firm says Coronavirus – latest updates See all our coronavirus coverage The UK is set to face short-term delays in delivery of the Pfizer/BioNTech coronavirus vaccine as the pharmaceutical company upgrades its production capacity. Pfizer is upscaling production at its plant …

UK to face short term delay in delivery of Pfizer vaccine Read More »

Tivicay approved in Europe in new dispersible tablet for children with HIV

ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV. The joint venture, majority-owned by GlaxoSmithKline with Pfizer and Shionogi as shareholders, said the European Commission had granted a marketing authorisation for the new formulation. These tablets are used in combination with other antiretroviral agents …

Tivicay approved in Europe in new dispersible tablet for children with HIV Read More »

Study says COVID-19 infection provides immunity, but people can transmit virus

Previous COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit the virus, according to a study by Public Health England. A first report from PHE’s SIREN study found antibodies from previous COVID-19 infection provide 83% protection against reinfection for at least five months. It found that reinfections …

Study says COVID-19 infection provides immunity, but people can transmit virus Read More »

Australia’s chief medical officer defends AstraZeneca’s Covid vaccine amid efficacy concerns

Australia has secured 54m doses of the vaccine some experts say is inferior to Pfizer’s mRNA vaccine, which Australia has bought just 10m doses of Covid hotspots Victoria; NSW hotspots; Queensland hotspots NSW and Sydney trend map: where cases are rising or falling Follow the Australia coronavirus live blog Australia’s chief medical officer Professor Paul …

Australia’s chief medical officer defends AstraZeneca’s Covid vaccine amid efficacy concerns Read More »

Pfizer/BioNTech vaccine may work against new virus mutation, scientists say

The Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in the UK and South Africa, according to research from the drugs giant. Findings of the lab study posted online have not yet been peer reviewed but provide some reassurance for countries like the UK, which are relying …

Pfizer/BioNTech vaccine may work against new virus mutation, scientists say Read More »

UK left trailing as EU quickly approves Moderna’s COVID-19 vaccine

The European Union has approved the coronavirus vaccine from Moderna, leaving the UK trailing because of changes to post-Brexit drug approval rules. With the UK reeling from one of the worst outbreaks of the disease, it’s a worrying situation for one of the countries worst hit by the pandemic that is relying on vaccines to …

UK left trailing as EU quickly approves Moderna’s COVID-19 vaccine Read More »

Britain could be mass-producing its Covid shot. Shame we junked our industrial base | Aditya Chakrabortty

The dire state of UK manufacturing has left us dependent on other nations. We may soon find out why some call this a ‘national security risk’ Everything now hinges on a vaccine: how many more Britons die, whether the NHS finally breaks, how long the UK stays locked down. All depends on how fast the …

Britain could be mass-producing its Covid shot. Shame we junked our industrial base | Aditya Chakrabortty Read More »

UK vaccine minister vows ‘massive uplift’ in number of jabs this week

Nadhim Zahawi says ‘absolute focus’ is to get 13.9 million people inoculated by mid-February Coronavirus – latest updates See all our coronavirus coverage The UK vaccine minister, Nadhim Zahawi, has pledged a “massive uplift” in the number of coronavirus vaccinations carried out this week as he said reaching the government’s target of 13.9m jabs offered …

UK vaccine minister vows ‘massive uplift’ in number of jabs this week Read More »

How is the Oxford Covid vaccine being deployed in England?

With jab to be administered to public for first time, we look at key questions about its rollout Coronavirus – latest updates See all our coronavirus coverage The biggest vaccination programme in the UK’s history will receive a major boost on Monday, with the first use of the Oxford/AstraZeneca Covid vaccine. We answer some key …

How is the Oxford Covid vaccine being deployed in England? Read More »

The Oxford Covid jab is delivered this week. But when will vaccines bring results?

Fall or rise in coronavirus cases will not initially be a good measure of efficacy, say scientists devising ways to audit progress Why is Britain delaying second doses of vaccine? Coronavirus – latest updates See all our coronavirus coverage People in Britain are set to get their first shots of the Oxford/AstraZeneca vaccine on Monday, …

The Oxford Covid jab is delivered this week. But when will vaccines bring results? Read More »

What difference will Oxford/AstraZeneca vaccine make in UK?

We look at how the introduction of a new vaccine in the fight against Covid will work Coronavirus – latest updates See all our coronavirus coverage The Oxford/AstraZeneca vaccine is central to the government’s plans for ending social distancing in the UK and returning to some sort of normality. It has invested in seven different …

What difference will Oxford/AstraZeneca vaccine make in UK? Read More »

Change in vaccine policy is a high-stakes gamble | Letters

The effectiveness of delaying the second dose of Covid vaccines must be carefully monitored, argues Dr Grizelda George, while Jan Mortimer and Jenny van Tinteren fear the move will increase distrust and uncertainty The manufacturer of the Pfizer/BioNTech vaccine has said its efficacy has only been assessed for two doses given three weeks apart. Therefore …

Change in vaccine policy is a high-stakes gamble | Letters Read More »

Questions hang over UK’s rollout of Oxford/AstraZeneca jab

Analysis: regulator surprises by approving 12-week gap between first and second shots of vaccine as well as Pfizer/BioNTech shot Coronavirus – latest updates See all our coronavirus coverage It’s a pragmatic solution to an incredibly urgent problem – how to immunise very large numbers of people at risk from a rampaging variant of Covid-19 in …

Questions hang over UK’s rollout of Oxford/AstraZeneca jab Read More »

UK prepares for decision on AZ/Oxford vaccine as COVID cases soar

The UK’s COVID-19 vaccination programme could get a speed boost, with the country’s drugs regulator expected to make a decision on a shot from Oxford University/AstraZeneca in the next few days. If the vaccine becomes available the UK will be able to step up its vaccination programme as large swathes of the country face draconian …

UK prepares for decision on AZ/Oxford vaccine as COVID cases soar Read More »

Government ‘operated illegal buy British policy’ over Covid contracts

Other firms better placed to supply antibody tests, argues case against health secretary Matt Hancock Coronavirus – latest updates See all our coronavirus coverage The government was operating an illegal “buy British” policy when it signed contracts with a small UK firm to supply Covid antibody tests, claim lawyers who have filed a case against …

Government ‘operated illegal buy British policy’ over Covid contracts Read More »

NHS pilots virtual assistant for flu jab bookings

More than 1,000 NHS patients have booked flu vaccinations using a virtual assistant as part of a pilot project in the south east of England. The pilot project, run in collaboration with GP practices in Buckinghamshire, Brent, and Greenwich, involved patients using the Ask NHS app, which is already used by more than 375,000 patients. …

NHS pilots virtual assistant for flu jab bookings Read More »

FDA aims for fast approval of Moderna’s COVID-19 shot after panel vote

The FDA is looking to quickly approve Moderna’s COVID-19 vaccine after it was unanimously backed by a panel of experts. Yesterday’s advisory panel meeting voted 20-0 in favour of approving Moderna’s vaccine and although the vote is non-binding, you could probably bet your house on the FDA backing the shot as it rarely goes against …

FDA aims for fast approval of Moderna’s COVID-19 shot after panel vote Read More »

British American Tobacco wins approval to test Covid vaccine on humans

Treatment grown on tobacco plants gets US backing for clinical study Coronavirus – latest updates See all our coronavirus coverage British American Tobacco has moved a step closer to producing a vaccine for coronavirus using tobacco plants, as it won approval in the US to begin testing on humans. The company behind cigarette brands including …

British American Tobacco wins approval to test Covid vaccine on humans Read More »

Scheme to get Covid vaccine to poorer countries at ‘high risk’ of failure

Risk assessment documents say cost, delays and shortages could lead to billions not vaccinated until 2024 Coronavirus – latest updates See all our coronavirus coverage The global scheme to deliver Covid-19 vaccines to poorer countries faces a “very high” risk of failure, potentially leaving billions of people with no access to vaccines until as late …

Scheme to get Covid vaccine to poorer countries at ‘high risk’ of failure Read More »

AbbVie begins trials of COVID-19 antibody therapy

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. In a joint statement, the biotech and the university said that the antibody, dubbed ABBV-47D11, will be developed for prevention and treatment of COVID-19 and related coronaviruses. AbbVie has …

AbbVie begins trials of COVID-19 antibody therapy Read More »

Family doctors begin COVID-19 immunisation drive in UK

The roll-out of the biggest vaccination programme in the history of the UK’s NHS is gathering pace, as family doctors and their teams begin taking delivery of Pfizer/BioNTech’s COVID-19 shot. In a statement the NHS said that GP practices in more than 100 parts of the country are taking delivery of the vaccine today. Some …

Family doctors begin COVID-19 immunisation drive in UK Read More »

Novartis/Incyte draw blank with Jakafi in COVID-19

Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against COVID-19, after it failed to cut complications or death in a phase 3 trial. Data from the phase 3 RUXCOVID study showed that there was no significant reduction in the proportion of COVID-19 patients on ruxolitinib plus …

Novartis/Incyte draw blank with Jakafi in COVID-19 Read More »

FDA advisers vote in favour of Pfizer/BioNTech COVID-19 shot

Advisers to the FDA have voted in favour of approving Pfizer and BioNTech’s COVID-19 vaccine, with a near-unanimous backing from an expert committee. While the decision of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) is non-binding, the FDA seldom goes against the ruling of its advisers when making regulatory decisions. However has were …

FDA advisers vote in favour of Pfizer/BioNTech COVID-19 shot Read More »

Can the UK deliver on the Covid vaccine rollout? | Stephen Buranyi

The challenge of delivering vaccines on this scale are hard, but are firmly within the world of logistics, engineering, and politics Coronavirus – latest updates See all our coronavirus coverage The UK has become the first country to approve one of the coronavirus vaccines that the entire world has been desperately waiting for. And on …

Can the UK deliver on the Covid vaccine rollout? | Stephen Buranyi Read More »

NHS told not to give Pfizer vaccine to extreme allergy sufferers after two people have reaction

Anyone scheduled to receive vaccine will be asked about history of allergic reactions Coronavirus – latest updates See all our coronavirus coverage Regulators have issued a warning that people who have a history of “significant” allergic reactions should not currently receive the Pfizer/BioNTech Covid-19 vaccine after two people who had the jab on Tuesday had …

NHS told not to give Pfizer vaccine to extreme allergy sufferers after two people have reaction Read More »

FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel

Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The gist of a briefing document published from FDA reviewers ahead of an expert advisory board …

FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel Read More »

Nine out of 10 in poor nations to miss out on inoculation as west buys up Covid vaccines

Billions unlikely to get jabs as rich countries secure 53% of most promising vaccines Coronavirus – latest updates See all our coronavirus coverage Nine out of 10 people in 70 low-income countries are unlikely to be vaccinated against Covid-19 next year because the majority of the most promising vaccines coming on-stream have been bought up …

Nine out of 10 in poor nations to miss out on inoculation as west buys up Covid vaccines Read More »

Leaders in the Life Sciences Speak about the Pandemic

We are in a global pandemic that is exposing major issues in the commercial environment in which healthcare companies operate, with changes that are completely altering the landscape for the long term. Our 3rd Annual Leaders in Life Sciences Roundtable consisted of eight industry leaders with diverse perspectives and experiences discussing these changes, their impacts, and best practices learned …

Leaders in the Life Sciences Speak about the Pandemic Read More »

FDA: Pfizer Covid vaccine data fits with guidance on emergency authorization

Comments raise hopes that the vaccine could soon be available to Americans aged 16 and above US Food and Drug Administration (FDA) staff said on Tuesday that data on Pfizer’s coronavirus vaccine was in line with its guidance on emergency use authorization, raising hopes it could soon be available to Americans aged 16 and above. …

FDA: Pfizer Covid vaccine data fits with guidance on emergency authorization Read More »

First COVID-19 vaccinations begin in UK hospitals

A 90-year-old woman has become the first person given a COVID-19 vaccine as part of the UK’s mass vaccination programme. Margaret Keenan was given the injection at 06:31 this morning at University Hospitals Coventry and Warwickshire NHS Trust. Keenan turns 91 next week and the BBC said she described receiving the shot as “the best …

First COVID-19 vaccinations begin in UK hospitals Read More »

Valneva accelerates Lyme disease vaccine R&D project with Pfizer

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Subject to approval from regulators the vaccine specialist said it plans the trial known as VLA15-221 as a randomised, observer-blind phase 2 study including around 600 healthy people …

Valneva accelerates Lyme disease vaccine R&D project with Pfizer Read More »

PureTech begins trial of potential ‘Long COVID’ drug as cases mount

As the pandemic drags on there are increasing concerns about “Long COVID” – where symptoms persist long after the initial infection has been fought off. PureTech has joined the effort to find ways to treat the scarring and inflammation that are thought to cause the ongoing symptoms such as shortness of breath and fatigue. After …

PureTech begins trial of potential ‘Long COVID’ drug as cases mount Read More »

How does the Pfizer/BioNTech vaccine work and who will get it?

Covid vaccine with an efficacy of almost 95% has been authorised by the UK medicines regulator Coronavirus – latest updates See all our coronavirus coverage The Pfizer/BioNTech Covid vaccine, which has an efficacy of almost 95%, has been authorised by the UK medicines regulator, making the UK the first western country to license a vaccine …

How does the Pfizer/BioNTech vaccine work and who will get it? Read More »

Oxford controversy is the first shot in international battle over vaccine efficiency

Trials will not reveal all the facts on prevention for each new drug – that process could last for years Coronavirus – latest updates See all our coronavirus coverage In a few days, researchers plan to solve a medical mystery that threatens to erupt into a major transatlantic battle. Scientists at Oxford University say they …

Oxford controversy is the first shot in international battle over vaccine efficiency Read More »

Different age groups may get different Covid vaccines, experts say

Oxford/AstraZeneca planning new trial of lower-dose jab to see how well it works in older people Coronavirus – latest updates See all our coronavirus coverage Concerns around the efficacy of the Oxford University/AstraZeneca coronavirus jab in older people could lead to different age groups being given different vaccines, experts have said. The partners announced last …

Different age groups may get different Covid vaccines, experts say Read More »

BioNTech’s Covid vaccine is a triumph of innovation and immigration | Hans-Werner Sinn

Pioneered by a Turkish-German couple, its significance exceeds its practical value The world took note when the German startup BioNTech announced its breakthrough in the development of a new type of vaccine to combat Covid-19. After testing tens of thousands of people, BioNTech’s vaccine has been shown to be 95% effective in providing protection for …

BioNTech’s Covid vaccine is a triumph of innovation and immigration | Hans-Werner Sinn Read More »

Will everyone in the world have access to a Covid vaccine? – video explainer

The hunt for a coronavirus vaccine is showing promise but it is premature to say the end of the pandemic is nigh. Several rich countries have signed a ‘frenzy of deals’ that could prevent many poor nations from getting access to immunisation until at least 2024. Also, many drug firms are potentially refusing to waive patents and other intellectual property rights …

Will everyone in the world have access to a Covid vaccine? – video explainer Read More »

‘Mistake’ led to AZ’s more effective lower-dose COVID-19 shot

AstraZeneca’s research chief has said that the more effective dosing regimen of its coronavirus vaccine was discovered by accident. According to Reuters, the AstraZeneca development team made a minor mistake that made them realise they could significantly boost the success rate of the vaccine, codenamed AZD1222. Results announced earlier this week showed that by giving …

‘Mistake’ led to AZ’s more effective lower-dose COVID-19 shot Read More »

FDA approves Roche’s Xofluza to prevent flu spreading in families

The FDA has approved a new use for Xofluza (baloxavir marboxil) from Roche’s Genentech unit, to prevent people developing flu after coming into contact with an infectious person. Xofluza has already been on the market for two years, and already had licensed uses to treat uncomplicated flu and those at high risk of complications. With …

FDA approves Roche’s Xofluza to prevent flu spreading in families Read More »

‘It’s a great day’: Oxford coronavirus vaccine volunteers on trial data

Trial participants react to news that Oxford AstraZeneca Covid vaccine has up to 90% efficacy Coronavirus – latest updates See all our coronavirus coverage Dan McAteer describes his reaction more as a sense of relief than elation when his phone pinged on Monday morning with a push alert reporting that the Oxford AstraZeneca vaccine has …

‘It’s a great day’: Oxford coronavirus vaccine volunteers on trial data Read More »

Oxford AstraZeneca results open up Covid vaccine to developing countries

Jab can be kept in fridge and is part of global initiative to distribute doses at limited cost Coronavirus – latest updates See all our coronavirus coverage The efficacy of the Oxford University/AstraZeneca vaccine opens the way for a cheap and more easily transportable vaccine to be made available to some of the world’s poorest …

Oxford AstraZeneca results open up Covid vaccine to developing countries Read More »

The Guardian view on coronavirus and vaccine scepticism: time to act | Editorial

Plans for mass immunisation against Covid-19 are developing fast, but concerns must be addressed In the 1960s, academics studying rumours drew inspiration from epidemiology. They noted how such stories spread through communities, “infecting” some individuals while others seemed immune, and how more resistant populations could stop their spread. Their insights have in turn been taken …

The Guardian view on coronavirus and vaccine scepticism: time to act | Editorial Read More »

Do mRNA vaccines for Covid signal a new era in disease prevention? | Adam Finn

No one knew whether mRNA technology would work against this virus – but it does. It’s an extraordinary moment for science Coronavirus – latest updates See all our coronavirus coverage The past few months have brought a number of scientific terms to public attention. We’ve had to digest R (a virus’s reproduction number) and PCR …

Do mRNA vaccines for Covid signal a new era in disease prevention? | Adam Finn Read More »

Trials to begin in UK for Covid antibody cocktail drug treatment

Scientists say jab could be used to protect those who cannot be given vaccines Coronavirus – latest updates See all our coronavirus coverage Major trials will begin this weekend of an antibody cocktail that scientists hope will protect people against Covid-19 and could be swiftly used in care homes or on cruise ships in the …

Trials to begin in UK for Covid antibody cocktail drug treatment Read More »

UK faces calls to drop opposition to patent-free Covid vaccines

Request will be made at WTO meeting in order to allow mass production of treatments Coronavirus – latest updates See all our coronavirus coverage The UK will be asked to reconsider its opposition to waiving intellectual property rights for Covid-19 vaccines and treatments at a World Trade Organization meeting on Friday, a move that would …

UK faces calls to drop opposition to patent-free Covid vaccines Read More »

Pfizer Covid-19 vaccine has 95% efficacy and is safe, further analysis shows

Among first 170 Covid cases in trial, eight had received vaccine and 162 were in placebo group Coronavirus – latest updates See all our coronavirus coverage The Pfizer/BioNTech vaccine against Covid-19 performs even better than previously thought, with 95% efficacy, equalling the early results from Moderna on Monday, according to an analysis of the final …

Pfizer Covid-19 vaccine has 95% efficacy and is safe, further analysis shows Read More »

ViiV could challenge Gilead with long-acting HIV PrEP shot

GlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge to Gilead’s HIV pre-exposure prophylaxis (PrEP) medicines after the FDA granted Breakthrough Therapy Designation for its long-acting injectable drug cabotegravir. In the trial cabotegravir was injected every eight weeks in a formulation that the company hopes will be more appealing than Gilead’s daily Truvada pill. …

ViiV could challenge Gilead with long-acting HIV PrEP shot Read More »

COVID-19: Helping to support momentum on antimicrobial innovation

To mark World Antimicrobial Awareness Week NovaBiotics’s Deborah O’Neil tells us why 2021 might be the year anti-infective drugs finally demonstrate their economic value.  COVID-19 has reminded the world how critical infectious disease is, from both a societal and economic standpoint. Cancer is rightly seen as one of the most pressing challenges of our time: …

COVID-19: Helping to support momentum on antimicrobial innovation Read More »

UK in ‘advanced discussions’ to buy Moderna Covid vaccine

Britain decided not to buy US vaccine and earliest it could be supplied to UK is spring 2021 Coronavirus – latest updates See all our coronavirus coverage The UK has not acquired the Moderna vaccine but is in “advanced discussions” to ensure British access, officials have said, while cautioning that no one in the UK …

UK in ‘advanced discussions’ to buy Moderna Covid vaccine Read More »

It’s the ‘vaccine hesitant’, not anti-vaxxers, who are troubling public health experts | Gaby Hinsliff

To make vaccination work, we must reach out to the naturally cautious – a bigger proportion than you might assume Coronavirus – latest updates See all our coronavirus coverage Lydia Guthrie is not very daring by nature. A psychotherapist and mother of two from Oxford, she couldn’t be persuaded into bungee jumping for all the …

It’s the ‘vaccine hesitant’, not anti-vaxxers, who are troubling public health experts | Gaby Hinsliff Read More »

Moderna Covid vaccine candidate almost 95% effective, trials show

US-based biotech firm is latest to reveal impressive results from phase 3 trials of jab Coronavirus – latest updates See all our coronavirus coverage The race for a coronavirus vaccine has received another shot in the arm with the US biotech firm Moderna becoming the latest to reveal impressive results from phase 3 trials of …

Moderna Covid vaccine candidate almost 95% effective, trials show Read More »

BioNTech vaccine scientist says jab could halve Covid transmission

Uğur Şahin ‘very confident’ vaccine candidate developed with Pfizer will cause big reduction in cases Coronavirus – latest updates See all our coronavirus coverage The scientist behind the first potential Covid-19 vaccine to clear interim clinical trials says he is “very confident” the jab will reduce transmission of the disease, perhaps by 50%, resulting in …

BioNTech vaccine scientist says jab could halve Covid transmission Read More »

Vaccination hesitancy is about lack of trust. Compulsion is not the answer | Kenan Malik

Better to build social solidarity than to dismiss reluctance to be immunised as ignorance Coronavirus – latest updates See all our coronavirus coverage “If a strain as deadly as the 1918 influenza emerges and people’s hesitancy to get vaccinated remains at the level it is today, a debilitating and fatal disease will spread.” So wrote …

Vaccination hesitancy is about lack of trust. Compulsion is not the answer | Kenan Malik Read More »

Lilly’s Monoclonal EUA

I’ve been meaning to write about what has to be called a regulatory mystery. Eli Lilly obtained an Emergency Use Authorization for its monoclonal antibody (bamlanivimab) against SARS-Cov-2, but (as detailed in this post) the dosage that they applied for was 700mg. Which is one-quarter of the dose that showed any efficacy against the primary …

Lilly’s Monoclonal EUA Read More »

BioNTech chief rejects Trump claim it delayed Covid vaccine news

Exclusive: Ugur Şahin says he and Pfizer CEO received results night before announcement Coronavirus – latest updates See all our coronavirus coverage The scientist behind the BioNTech/Pfizer coronavirus vaccine has defended his company from Donald Trump’s accusation that it deliberately delayed news of its rapid progress until after the election, saying “we don’t play politics”. …

BioNTech chief rejects Trump claim it delayed Covid vaccine news Read More »

The Covid vaccine will benefit humanity – we should all own the patent | Owen Jones

The pharmaceutical industry has long made exorbitant profits by free-riding on research carried out by the public sector Hooray for Pfizer! As news of a vaccine potentially offering 90% protection against Covid-19 offers a life raft for lockdown-weary humanity, perhaps those home-drawn posters on people’s windows thanking the NHS will soon be applauding big pharma …

The Covid vaccine will benefit humanity – we should all own the patent | Owen Jones Read More »

Why a Covid vaccine doesn’t mean the end of face masks yet | David Salisbury

Despite the Pfizer breakthrough, social distancing and remote working won’t disappear overnight Coronavirus – latest updates See all our coronavirus coverage The news this week that the Pfizer/BioNTech vaccine protected more than 90% of recipients is of huge importance. The vaccine efficacy is higher than we had hoped for. There appear to be no safety …

Why a Covid vaccine doesn’t mean the end of face masks yet | David Salisbury Read More »

Where will poorer countries stand in the queue for a Covid-19 vaccine? | Clare Wenham and Mark Eccleston-Turner

The lion’s share of the potential Pfizer vaccine is already claimed by high-income nations The news that joint efforts by the US pharmaceutical company Pfizer and the German biotech company BioNtech have produced a vaccine that is 90% effective at protecting people from Covid-19 has been understandably applauded – in spite of the caveats. Pfizer …

Where will poorer countries stand in the queue for a Covid-19 vaccine? | Clare Wenham and Mark Eccleston-Turner Read More »

Pfizer and BioNTech could make $13bn from coronavirus vaccine

Johnson & Johnson and AstraZeneca pledged to make their vaccines available on a not-for-profit basis Coronavirus – latest updates See all our coronavirus coverage The US drugmaker Pfizer and the German biotech firm BioNTech stand to bring in nearly $13bn (£9.8bn) in global sales from their coronavirus vaccine next year, which will be evenly split …

Pfizer and BioNTech could make $13bn from coronavirus vaccine Read More »

Pfizer and BioNTech’s vaccine poses global logistics challenge

Europe and US create vast facilities for Covid-19 vaccine but poorer nations lack infrastructure say experts Coronavirus – latest updates See all our coronavirus coverage Two vast football-pitch-sized facilities equipped with hundreds of large freezers in Kalamazoo, Michigan, and Puurs, Belgium, will be the centres of the huge effort to ship the coronavirus vaccine developed …

Pfizer and BioNTech’s vaccine poses global logistics challenge Read More »

The Guardian view on the Covid vaccine breakthrough: making it work | Editorial

At last, there is hope of an end to this pandemic. Scientists appear to have performed an amazing feat, the rest of us must do our best too Medicine is only partly a matter of science; it is, very much, the business of people. The inspiring news that a Covid vaccine appears within reach, with …

The Guardian view on the Covid vaccine breakthrough: making it work | Editorial Read More »

Will enough people in the UK take the Covid-19 jab?

The UK usually has a high take-up for vaccines, experts say, but there are fears over misinformation and scepticism Coronavirus: anti-vaxxers seek to discredit Pfizer’s vaccine Coronavirus – latest updates See all our coronavirus coverage The spread of scepticism and misinformation about coronavirus and the development of a vaccine for it has raised questions about …

Will enough people in the UK take the Covid-19 jab? Read More »

Cautious optimism over Covid-19 vaccine trials | Letters

Readers respond to news that an interim analysis has shown Pfizer/BioNTech’s vaccine candidate was 90% effective in protecting people from transmission of the virus in global trials The media have been awash with stories about the apparent success of the Pfizer Covid vaccine following the publication of preliminary trial outcomes (Hopes rise for end of …

Cautious optimism over Covid-19 vaccine trials | Letters Read More »

6 key questions about the Pfizer/BioNTech Covid-19 vaccine

There are grounds for optimism but also several unknowns around this coronavirus vaccine Coronavirus – latest updates See all our coronavirus coverage Hopes that the end of the coronavirus pandemic has become nearer have soared after the news that a coronavirus vaccine was found to be 90% effective in global trials. Although there is definite …

6 key questions about the Pfizer/BioNTech Covid-19 vaccine Read More »

What does the Pfizer Covid vaccine breakthrough mean for Australia?

Interim results show vaccine to be 90% effective, but findings have not been peer-reviewed, Australia has only secured enough for five million people, and there are concerns around its storage temperature • Pfizer says vaccine is 90% effective • What has Pfizer’s vaccine trial found? • Vaccine announcement is cause for cautious celebration News that …

What does the Pfizer Covid vaccine breakthrough mean for Australia? Read More »

Don’t Make Mine Mink

There’s a situation in Denmark that deserves some epidemiological attention. Now, put me in the (rather large) category who did not realize how large the Danish mink industry is – or that a Danish mink industry existed at all – but there are plenty of mink farmers there and millions of mink. 40% of world …

Don’t Make Mine Mink Read More »

UK could get COVID-19 vaccines early next year, ahead of European countries

COVID-19 vaccines could be approved and available early next year in the UK ahead of European countries, after its national regulator began its own rolling reviews of shots from AstraZeneca and Moderna. AstraZeneca has confirmed that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has begun a fast-track rolling review of its AZD1222, the …

UK could get COVID-19 vaccines early next year, ahead of European countries Read More »

Regeneron’s COVID-19 antibody cocktail therapy hits safety problem

Regeneron’s coronavirus antibody cocktail therapy against COVID-19, famously used to treat president Donald Trump, has hit a safety issue after independent safety experts recommended it should not be given to high-risk patients in a late-stage clinical trial. It’s the latest blow for antibody therapies against COVID-19 after Eli Lilly last week announced it won’t resume …

Regeneron’s COVID-19 antibody cocktail therapy hits safety problem Read More »

Oxford Covid vaccine works in all ages, trials suggest

Vaccine being trialled by Oxford University and AstraZeneca offers hope for all age groups Coronavirus – latest updates See all our coronavirus coverage One of the world’s leading Covid-19 experimental vaccines produces an immune response in both older and young adults, raising hopes of a path out of the gloom and economic destruction wrought by …

Oxford Covid vaccine works in all ages, trials suggest Read More »

Are we near to having a vaccine for Covid-19?

Even a once bullish PM is now not so optimistic but there are promising signs of a vaccine on the horizon Coronavirus – latest updates See all our coronavirus coverage In March, Boris Johnson said we would turn the tide in 12 weeks and “send the coronavirus packing” and by May ministers were boasting of …

Are we near to having a vaccine for Covid-19? Read More »

Gilead’s COVID-19 drug Veklury falls short in WHO’s global trial

Gilead’s Veklury (remdesivir) has failed to produce an effect on hospital stay and mortality in COVID-19 patients in a large global trial, casting doubt on previous supportive study findings. The results from the World Health Organization’s large Solidarity trial are yet to be peer reviewed but were posted online on a preprint server. Interim findings …

Gilead’s COVID-19 drug Veklury falls short in WHO’s global trial Read More »

Regeneron’s antibody cocktail approved by FDA for Ebola

An antibody cocktail from Regeneron has been approved by the FDA as the first treatment for Ebola, offering hope that a similar approach could be used to combat COVID-19. The FDA approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for treatment of infection caused by Zaire ebolavirus in adults and children including newborns of mothers who test …

Regeneron’s antibody cocktail approved by FDA for Ebola Read More »

Coronavirus re-infection case confirmed in the US

There is growing evidence that the coronavirus may be able to re-infect patients, and a new instance of a second infection has been confirmed in the US.  It is the fifth confirmed reinfection worldwide after at least four other cases were confirmed in Belgium, the Netherlands, Hong Kong and Ecuador. The latest case was recorded …

Coronavirus re-infection case confirmed in the US Read More »

NHS coronavirus tests threatened by Roche supply chain glitch

Pharmaceutical firm reports ‘significant drop in processing capacity’ of reagents, kits and swabs Coronavirus – latest updates See all our coronavirus coverage Concerns have been raised over the supply of vital testing materials for a range of conditions, including Covid-19, following a supply chain problem with the pharmaceutical company Roche. On Tuesday, Roche said it …

NHS coronavirus tests threatened by Roche supply chain glitch Read More »

Trump’s steroid Covid treatment adds to confusion over health

Dexamethasone ‘normally reserved for people going into respiratory failure’, says expert Trump coronavirus treatment – live updates The latest intervention from Donald Trump’s medical team has been to put the president on dexamethasone, a steroid that is proven, thanks to the UK’s Recovery trial, to benefit Covid-19 patients who are having breathing difficulties. But the …

Trump’s steroid Covid treatment adds to confusion over health Read More »

Anti-Covid treatments being given to Trump are still unproven, say experts

Neither remdesivir nor REGN-COV2 have completed large-scale randomised trials, say UK scientists Coronavirus – latest updates See all our coronavirus coverage Scientists still lack conclusive proof that the two anti-Covid drugs given to Donald Trump are clinically effective. UK researchers point out that both medicines – remdesivir and REGN-COV2 – have still to complete the …

Anti-Covid treatments being given to Trump are still unproven, say experts Read More »

UK doing more than most to help poor get Covid vaccine, study finds

Campaign scoring countries for global access efforts calls for more British transparency Coronavirus – latest updates See all our coronavirus coverage The UK is doing more than most countries to support access to Covid vaccines for the poorest populations in the world, but it is not transparent enough about the deals it is doing at …

UK doing more than most to help poor get Covid vaccine, study finds Read More »

Pharmacies in England pause online flu jab bookings as demand soars

Boots, LloydsPharmacy and Well Pharmacy report unprecedented take-up and many chemists run out of stock Coronavirus – latest updates See all our coronavirus coverage Pharmacies across England are struggling to keep up with the demand for the flu vaccine, pausing online bookings and limiting it to those most in need. The country’s three largest pharmacy …

Pharmacies in England pause online flu jab bookings as demand soars Read More »

Australia’s drug regulator TGA approves Covid tests that deliver results in 15 minutes

Healthcare workers and health departments will be among the first to use the rapid antigen tests Full Australian Covid stats; Covid restrictions state by state Follow our global live blog Vic cases map; NSW cases map NSW hotspots list; Qld hotspots list Australia’s drugs regulator has approved four rapid antigen Covid-19 tests for distribution throughout …

Australia’s drug regulator TGA approves Covid tests that deliver results in 15 minutes Read More »

Beware of big pharma in rush for Covid-19 vaccine | Letter

Heidi Chow on why the pharmaceutical industry must not be left in the driving seat to supply an effective Covid-19 vaccine The biggest gamble that governments are taking is not on specific vaccine candidates, but on the pharmaceutical industry itself (The Covid-19 vaccine gamble: where bets have been placed and why, 11 September). The pharmaceutical …

Beware of big pharma in rush for Covid-19 vaccine | Letter Read More »

Show more empathy to boost confidence in vaccines, scientists told

Expert behind vaccine confidence report points to halting of Oxford Covid trial as example Doctors and scientists need to show more empathy towards volunteers in coronavirus vaccine trials who fall ill if the public is to have full confidence in the safety of the vaccines being developed, say experts. The temporary halting of the Oxford …

Show more empathy to boost confidence in vaccines, scientists told Read More »

Oxford Covid-19 vaccine is still possible this year, says AstraZeneca chief

Pharmaceutical firm’s boss says 2020 deadline possible if regulators move fast Coronavirus – latest updates See all our coronavirus coverage AstraZeneca’s coronavirus vaccine could still be available by the end of the year, or early next year, according to the company’s chief executive, Pascal Soriot, despite clinical trials being paused after a volunteer fell ill. …

Oxford Covid-19 vaccine is still possible this year, says AstraZeneca chief Read More »

Oxford Covid vaccine trial suspension: what happens next?

Tests have been paused after a UK volunteer became ill. How will it affect the search for a cure? The AstraZeneca vaccine trial has been paused – should we be worried? Coronavirus – latest updates See all our coronavirus coverage One of the volunteers in the UK has become ill and it is crucial that …

Oxford Covid vaccine trial suspension: what happens next? Read More »

The Oxford University AstraZeneca Covid-19 vaccine trial has been paused – should we be worried?

Is this the end for hopes of an early breakthrough in the race to find a coronavirus drug? The halt in development of the University of Oxford’s Covid-19 vaccine due to a possible adverse reaction in a trial participant has triggered fears of a delay in finding a solution to coronavirus restrictions. A spokesman for …

The Oxford University AstraZeneca Covid-19 vaccine trial has been paused – should we be worried? Read More »

Oxford University Covid vaccine trial put on hold due to possible adverse reaction in participant

A spokesman for AstraZeneca, the company working on the coronavirus vaccine, said pausing trials was common during vaccine development The development of a promising Covid-19 vaccine has been put on hold due to a possible adverse reaction in a trial participant. A spokesman for AstraZeneca, the company working with a team from Oxford University, told …

Oxford University Covid vaccine trial put on hold due to possible adverse reaction in participant Read More »

AstraZeneca starts Covid-19 antibody drug trial in UK

Volunteers are receiving doses of drug, which has potential both as a vaccine and a treatment Coronavirus – latest updates See all our coronavirus coverage The pharmaceutical group AstraZeneca has started a clinical trial of a drug to help prevent and treat Covid-19, with the first volunteers already receiving doses. The company, which is separately …

AstraZeneca starts Covid-19 antibody drug trial in UK Read More »

Six of the most promising treatments for Covid-19 so far

While a cure-all drug or therapy is a long way off, there have been some breakthroughs Many different drugs and therapies are being trialled and used on patients with Covid-19. There are some positive results, which may be beginning to bring the hospital death toll down, but there is still a long way to go …

Six of the most promising treatments for Covid-19 so far Read More »

Oxford University Covid-19 vaccine firm denies Trump talks

AstraZeneca says it has not discussed ‘emergency use authorisation’ with the US Coronavirus – latest updates See all our coronavirus coverage The company manufacturing the Oxford University coronavirus vaccine has denied it is in talks with the Trump administration about fast-tracking its vaccine for emergency use ahead of November’s presidential elections. With both Russia and …

Oxford University Covid-19 vaccine firm denies Trump talks Read More »

Coronavirus pharma news round-up 21/08/20

New insights into smell and taste loss symptoms, artificial intelligence and further encouraging data from a vaccine candidate hit the headlines this week as the COVID-19 coronavirus pandemic continues. Here we highlight the biggest R&D, market access and digital coronavirus news of the past week. Pfizer and BioNTech have said their COVID-19 vaccine could be …

Coronavirus pharma news round-up 21/08/20 Read More »

Pfizer/BioNTech say COVID-19 jab on track for approval by year-end

Pfizer and BioNTech have said their COVID-19 vaccine could be ready for regulators to review by October and approved by the end of the year after releasing more favourable data from an early-stage trial. There are no vaccines approved for COVID-19 and governments across the world are striking deals with various manufacturers to get early …

Pfizer/BioNTech say COVID-19 jab on track for approval by year-end Read More »

Here’s everything you need to know about the potential Oxford University Covid vaccine

The vaccine is designed to mimic the coronavirus and train the immune system to react if a person is later infected Sign up for Guardian Australia’s coronavirus email Download the free Guardian app to get the most important news notifications The vaccine developed and tested by a team at Oxford University is one of the …

Here’s everything you need to know about the potential Oxford University Covid vaccine Read More »

Smell and taste loss could help identify COVID-19 at airports, say researchers

Smell and taste loss associated with COVID-19 differs from that experienced by patients with common colds or flu, according to researchers who said the symptom could be used to quickly identify coronavirus infections in settings such as airports or emergency departments. The study published in the journal Rhinology, was published as London’s Heathrow Airport unveiled …

Smell and taste loss could help identify COVID-19 at airports, say researchers Read More »

Could AI avert a future coronavirus pandemic?

Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses? This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. The Corona Accelerated R&D in Europe (CARE) has been hastily set up by …

Could AI avert a future coronavirus pandemic? Read More »

UK signs coronavirus vaccine deals with J&J and Novavax

The UK is to buy millions more doses of potential coronavirus vaccines from Johnson & Johnson and Novavax, with the latter expanding its manufacturing operation in the country. Johnson & Johnson’s Janssen pharmaceuticals unit will supply an initial 30 million doses on a not-for-profit basis for emergency use in the pandemic, with an option for …

UK signs coronavirus vaccine deals with J&J and Novavax Read More »

UK agrees deals for 90m doses of two potential coronavirus vaccines

Government secures early access to those being developed by Novavax and Janssen Coronavirus – latest updates See all our coronavirus coverage The UK government has reached agreements it says will give British citizens early access to 90m doses of two more potential Covid-19 vaccines. The vaccines are being developed by the US biotech company Novavax …

UK agrees deals for 90m doses of two potential coronavirus vaccines Read More »

Around 3.4m people infected with coronavirus in England – study

Just under 6% of England’s population – around 3.4 million people – had been infected with coronavirus by the end of June according to an estimate based on antibody tests. More than 100,000 people tested themselves for antibodies against the SARS-CoV-2 virus that can lead to COVID-19. The results from the study by Imperial College, …

Around 3.4m people infected with coronavirus in England – study Read More »

Scepticism as Russia claims coronavirus vaccine breakthrough with Sputnik V

Russia has become the first country in the world to approve a coronavirus vaccine, amid scepticism from international experts who have been unable to review or verify clinical data from the jab called ‘Sputnik V’. According to press reports the vaccine has been tested on one of President Vladimir Putin’s daughters. But World Health Organization …

Scepticism as Russia claims coronavirus vaccine breakthrough with Sputnik V Read More »

Gilead files COVID-19 drug remdesivir with FDA

Gilead has filed its COVID-19 drug remdesivir with the FDA, to treat patients with severe disease, under the brand name Veklury. The drug is currently available to US patients under an Emergency Use Authorisation for treatment of hospitalised patients with severe COVID-19. This filing is the last part of a rolling submission with the FDA …

Gilead files COVID-19 drug remdesivir with FDA Read More »

The Guardian view on Brexit bureaucracy: tied up in red tape | Editorial

Businesses already struggling with the fallout from Covid-19 will be forced to deal with a mountain of new bureaucracy in the middle of a deep recession The government did not quite achieve the Brexit breakthrough it was seeking on Friday, when there was hope that a fast-tracked trade agreement with Japan might be reached. But …

The Guardian view on Brexit bureaucracy: tied up in red tape | Editorial Read More »

Pfizer signs deal with Gilead to manufacture COVID-19 antiviral remdesivir

Pfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is also being tested in combination with other drugs in an effort to fight the pandemic. Under the terms of the agreement Pfizer will become one of several external partners who manufacture the investigational treatment for the disease. …

Pfizer signs deal with Gilead to manufacture COVID-19 antiviral remdesivir Read More »

Novavax says COVID-19 vaccine could be approved by year-end

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by year-end. The US biotech is gearing up to produce two billion doses of the vaccine in 2021 following the results from its vaccine candidate, codenamed …

Novavax says COVID-19 vaccine could be approved by year-end Read More »

Regeneron’s Monoclonal Antibody Cocktail in Primates

I’m very glad to see some data emerging on the monoclonal antibody therapies that have been in the works. Regeneron  and Eli Lilly/Abcellera are two of the front-runners in this field, which could pick up some very much needed slack while the many vaccine trials are going on. And late yesterday a preprint emerged from …

Regeneron’s Monoclonal Antibody Cocktail in Primates Read More »

Covid-19: Gilead Sciences urged to study drug that showed promise with cats

Activists accuse company of pushing remdesivir to boost profit GS-441524 has been used to treat a coronavirus in cats Coronavirus – latest global updates Activists are calling on the pharmaceutical firm Gilead Sciences to study a drug for the treatment of Covid-19 that showed promise in curing cats of a coronavirus. The drug, called GS-441524, …

Covid-19: Gilead Sciences urged to study drug that showed promise with cats Read More »

Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisition

Gilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – but revenues are declining as the pandemic bit into sales of its hepatitis C drugs. Product sales in Q2 were down nearly 10% compared with last year to just over $5 billion, and the company recorded a …

Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisition Read More »

Coronavirus Challenges in Primates, Compared

We have a sudden influx over the last few days of preclinical rhesus challenge studies with various coronavirus vaccines, and it’s only natural to try to compare them. I have worked up a table with all four of the current results and the previously reported SinoVac inactivated virus vaccine, whose rhesus challenge numbers were officially …

Coronavirus Challenges in Primates, Compared Read More »

Understanding COVID-19 and varying responses across the globe

While lockdown eases across England, local lockdowns are becoming an ever-growing threat across the country. This is a unique response in comparison to other countries across the world and could be indicative of a second spike in infections. At the beginning of the pandemic, The London School of Hygiene and Tropical Medicine launched a course …

Understanding COVID-19 and varying responses across the globe Read More »

Coronavirus: UK signs deal for 60m doses of potential vaccine

GlaxoSmithKline and Sanofi Pasteur could supply vaccine by early next year if it is successful Coronavirus – latest updates See all our coronavirus coverage The government has signed a deal with the pharmaceutical firms GlaxoSmithKline (GSK) and Sanofi Pasteur for 60m doses of a potential Covid-19 vaccine. If the vaccine proves successful, the UK could …

Coronavirus: UK signs deal for 60m doses of potential vaccine Read More »

Covid-19 is Big Pharma’s chance to impress. But who’ll do best?

AstraZeneca and GSK both release results this week. But picking winners in the sector may be complicated It was the press announcement heard around the world: a potential Covid-19 vaccine from the University of Oxford and pharmaceutical company AstraZeneca had not only been “tolerated” by patients, but “generated robust immune responses against the Sars-CoV-2 virus …

Covid-19 is Big Pharma’s chance to impress. But who’ll do best? Read More »

‘Major’ breakthrough in Covid-19 drug makes UK professors millionaires

Synairgen’s share price rises 540% on morning of news of successful drugs trial Coronavirus – latest updates See all our coronavirus coverage Three professors at the University of Southampton school of medicine have this week made a “major breakthrough” in the treatment of coronavirus patients and become paper millionaires at the same time. Almost two …

‘Major’ breakthrough in Covid-19 drug makes UK professors millionaires Read More »

The world needs a ‘people’s vaccine’ for coronavirus, not a big-pharma monopoly | Helen Clark and Winnie Byanyima

AstraZeneca and others should not own a lucrative patent on a medicine that is needed by poor as well as rich nations • See all our coronavirus coverage • Helen Clark is a former prime minister of New Zealand and Winnie Byanyima is UN undersecretary general To bring an end to the pandemic, the world …

The world needs a ‘people’s vaccine’ for coronavirus, not a big-pharma monopoly | Helen Clark and Winnie Byanyima Read More »

Bacteria and Colon Cancer

Let’s catch on some non-coronavirus research today with an interesting approach against a very bad disease, metastatic colon cancer. This new paper (from groups at Virginia Tech and Wake Forest) adds to our understanding of something that’s been noticed for some time: colon cancer tissue is often infected with Fusobacterium nucleatus. This bacterium (an anaerobic Gram-negative …

Bacteria and Colon Cancer Read More »

New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19

Throughout history, infectious diseases caused by pathogens such as bacteria or viruses have taken a devastating toll on the lives and security of people around the world. With the ongoing COVID-19 pandemic gripping the world, we are experiencing a challenging situation that we haven’t seen since the influenza pandemic of 1918-1919, when a third of …

New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19 Read More »

More Pfizer Phase I Results: Antibodies, Viral Mutations, and T Cells

Recent posts here have gone into Moderna’s Phase I vaccine data, Pfizer’s Phase I vaccine data, what we don’t know yet about the relationship between T-cells, antibodies, and immunity to the coronavirus, and some new data that are starting to fill in those gaps. This morning comes a new preprint from the Pfizer/BioNTech team that …

More Pfizer Phase I Results: Antibodies, Viral Mutations, and T Cells Read More »

More on T Cells, Antibody Levels, and Our Ignorance

I wrote here about the reports of rather short antibody persistence in recovering coronavirus patients, and what’s been coming out in the two weeks since then has only made this issue more important. In that post, I was emphasizing that although we can measure antibody levels, we don’t know how well that correlates with exposure …

More on T Cells, Antibody Levels, and Our Ignorance Read More »

WHO says trials show malaria and HIV drugs don’t cut Covid-19 hospital deaths

Hydroxychloroquine and lopinavir/ritonavir not found to help patients in hospital Coronavirus – latest updates See all our coronavirus coverage The World Health Organization (WHO) said on Saturday that it was discontinuing its trials of the malaria drug hydroxychloroquine and combination HIV drug lopinavir/ritonavir for patients in hospital with Covid-19 after they failed to reduce mortality. …

WHO says trials show malaria and HIV drugs don’t cut Covid-19 hospital deaths

Read More »

Oxford offers best hope for Covid-19 vaccine this year, MPs told

University is leading rivals but first drugs may not work fully, says vaccine taskforce chair Coronavirus – latest updates See all our coronavirus coverage Oxford University is leading the world in developing a vaccine against Covid-19 and offers the best chance of having something protective against the virus as we go into winter, MPs have …

Oxford offers best hope for Covid-19 vaccine this year, MPs told Read More »

Demand for flu vaccine soars as countries plan for second Covid-19 wave

Manufacturers warn they will struggle to meet demand as governments seek to ease pressure on health services Coronavirus – latest updates See all our coronavirus coverage Fears of a second wave of coronavirus have sparked a global scramble for influenza shots from countries that hope to vaccinate great swathes of the population to reduce pressure …

Demand for flu vaccine soars as countries plan for second Covid-19 wave Read More »

The Lancet’s editor: ‘The UK’s response to coronavirus is the greatest science policy failure for a generation’

Richard Horton does not hold back in his criticism of the UK’s response to the pandemic and the medical establishment’s part in backing fatal government decisions Coronavirus – latest updates See all our coronavirus coverage There is a school of thought that says now is not the time to criticise the government and its scientific …

The Lancet’s editor: ‘The UK’s response to coronavirus is the greatest science policy failure for a generation’

Read More »

FLU-PRO©: InFLUenza Patient-Reported Outcome

Access the on-demand webinar now https://bit.ly/FLU-PRO The FLU-PRO is a self-administered patient-reported outcome measure (PRO) to quantify symptom severity in influenza and influenza-like illness. The instrument was developed by a team of academic investigators spanning multiple sites across many countries under the direction of Dr. John H. Powers of George Washington University and the University …

FLU-PRO©: InFLUenza Patient-Reported Outcome Read More »

Healthcare Headlines: November 2019

<h2 class="heading-medium">Medicare Shared Savings ACOs Generated $1.7b In Savings In 2018 </h2> <p>CMS announced that the 2018 Medicare Shared Savings Program generated $1.7 billion in total savings. It also reported that ACOs in the shared savings and risk-based models saw reductions in per-enrollee spending. ACOs that took on downside risk generated more savings than ACOs …

Healthcare Headlines: November 2019 Read More »